Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13342
Abstract: The first‐line standard treatment of non‐small cell lung cancer (NSCLC) with EGFR mutation is EGFR‐tyrosine kinase inhibitors (TKIs). However, most patients will develop acquired resistance after 9–13 months. This study investigated novel molecular mechanisms of acquired… read more here.
Keywords: egfr; tki resistant; resistance egfr; line ... See more keywords
Abstract 1827: Direct activation of the tumor suppressor protein phosphatase 2A as a therapeutic strategy for TKI-resistant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1827
Abstract: Most lung adenocarcinoma (LUAD) patients develop acquired resistance to tyrosine kinase inhibitors (TKI) via mechanisms enabling the sustained activation of the MAPK and PI3K oncogenic pathways downstream of the tyrosine kinase EGFR. The tumor suppressor… read more here.
Keywords: lung adenocarcinoma; tki resistant; activation; tumor ... See more keywords
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-21-1429
Abstract: HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne… read more here.
Keywords: patritumab deruxtecan; egfr tki; deruxtecan paving; tki resistant ... See more keywords
The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26637
Abstract: Background Enhancing the chemosensitivity in the patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant lung adenocarcinoma (LUAD) is pivotal in achieving their successful therapeutic outcome. We aimed to explore the mechanisms regarding the… read more here.
Keywords: tki resistant; p22phox; chemosensitivity; egfr tki ... See more keywords
Corrigendum: TKI-Resistant Renal Cancer Secretes Low-Level Exosomal miR-549a to Induce Vascular Permeability and Angiogenesis to Promote Tumor Metastasis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cell and Developmental Biology"
DOI: 10.3389/fcell.2021.726535
Abstract: [This corrects the article DOI: 10.3389/fcell.2021.689947.]. read more here.
Keywords: resistant renal; tki resistant; corrigendum tki; cancer secretes ... See more keywords
Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14184423
Abstract: Simple Summary The introduction of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of lung cancer. Nevertheless, TKI resistance impedes therapeutic efficacy and its underlying mechanisms remain unclear. This review summarizes… read more here.
Keywords: lung cancer; egfr tki; tki resistant; noncoding rnas ... See more keywords
Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer"
DOI: 10.7150/jca.37417
Abstract: It is known that mammalian target of rapamycin (mTOR) signaling plays an important role in NSCLC cells proliferation. Torin2 is a second-generation ATP-competitive inhibitor which is selective for mTOR activity. In this study, we investigated… read more here.
Keywords: tki resistant; mtor signaling; proliferation; torin2 ... See more keywords